|
Synonyms: Jinlitai® | JMT-103 | JMT103
narlumosbart is an approved drug (China (2023))
Compound class:
Antibody
Comment: Narlumosbart (JMT103) is a fully human IgG4κ anti-RANKL (receptor activator of nuclear factor kappa-Β ligand) monoclonal antibody. It blocks the RANK/RANKL protein-protein interaction and thereby reduces pathological osteoclastogenesis in bone cancer.
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (China (2023)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 12344 | narlumosbart |
| Synonyms |
| Jinlitai® | JMT-103 | JMT103 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 1357 |
| Other databases | |
| GtoPdb PubChem SID | 491299866 |
| Search PubMed clinical trials | narlumosbart |
| Search PubMed titles | narlumosbart |
| Search PubMed titles/abstracts | narlumosbart |
